{"id":"W3087466624","doi":"10.1016/s1470-2045(20)30541-6","title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":498,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; Université Laval; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"Foundation Medicine; EMD Serono; Pharmacyclics; Genentech; AstraZeneca; EUSA Pharma; Astellas Pharma; Eisai; INOVIO Pharmaceuticals; AstraZeneca España; Pfizer; Incyte; Ipsen; Clovis Oncology; Les Laboratories Pierre Fabre; Endocyte; Sanofi; Exelixis; GlaxoSmithKline; Celldex Therapeutics; Amgen; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Tremelimumab; Chemotherapy; Metastatic Urothelial Carcinoma; Oncology; Open label; Internal medicine; Urology; Carcinoma; Randomized controlled trial; Urothelial carcinoma; Cancer; Immunotherapy; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001503286,0.001563159,0.002561862,0.0002960632,0.0003382073,0.001031663,0.001013101,0.001281164,0.006124247],"category_scores_gemma":[0.001394309,0.0004722574,0.001572328,0.0003368479,0.00107963,0.001196402,0.0004974237,0.003295342,0.0008755295],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001272941,"about_ca_system_score_gemma":0.001061235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001843355,"about_ca_topic_score_gemma":0.006138458,"domain_scores_codex":[0.9994072,0.0003637758,0.00001878439,0.00009063294,0.00003150915,0.00008811429],"domain_scores_gemma":[0.9992583,0.0002340332,0.0001327772,0.00004810468,0.00002875649,0.0002979978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9716563,0.004888372,0.0006650267,0.0005408808,0.001130055,0.00005623734,0.00008133944,0.0005306606,0.002297896,0.0001725518,0.00111414,0.01686671],"study_design_scores_gemma":[0.9250899,0.07020089,0.002309826,0.00003809661,0.0004186766,0.0000582049,0.00004570129,0.0004919448,0.0003142656,0.0002236947,0.0007916984,0.00001694378],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991594,0.00324441,0.0002525643,0.0008980985,0.0004315309,0.001014743,0.0006576888,0.00005647825,0.001850486],"genre_scores_gemma":[0.9883909,0.002200197,0.0007923212,0.0009934204,0.0002447754,0.001387848,0.0009740965,0.00002125912,0.004995266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006124247,"threshold_uncertainty_score":0.02048767,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09417910979039026,"score_gpt":0.3763797989152469,"score_spread":0.2822006891248566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}